Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Don Haut joined AskBio in March 2020 & acquired October 2020

<< Previous

Bullboard Posts

Next >>

Post by themagicboxon Jan 07, 2021 10:12am

230 Views

Post# 32241333

Don Haut joined AskBio in March 2020 & acquired October 2020

Its interesting that he joined AskBio in March 2020 as Chief Business Officer to lead its business development strategy and execution.

AskBio was aquired by Bayer for $4billion, which was annoucned in October 2020 i.e. 7 months later.

While you cant make a direct comparison with accuracy, directionally however, if we were to apply that timeline to ATE, we might get a deal in August.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features